To evaluate the influence of RASi on NAFLD development/progression across different RASi types, we stratified NAFLD development/progression cases and each corresponding control according to ACEIs-only, ARBs-only, and ARB users who had switched from ACEIs (Table 4). The gene discussed is MMP19; the disease is metabolic dysfunction-associated steatotic liver disease.